University of Utah Research v. Ambry Genetics Corporation, No. 14-1361 (Fed. Cir. Dec. 17, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Plaintiffs are the University of Utah Research Fou n- dation, The Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, Endorecherche, Inc., and Myriad Genetics, Inc. (collective- ly “Myriad”) . Myriad owns U.S. Patent No. 5,753,441 (“the ’4 41 patent”) , U.S. Patent No. 5,747,282 (“the ’282 patent”), and U.S. Patent No. 5,837,492 (“the ’492 p a- tent”), which cover compositions of matter and methods relating to the BRCA1 and BRCA2 genes .